DBV Technologies
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood.
Filings
179 filings
- DBV Technologies Reports First Quarter 2025 Financial ResultsEarnings releaseFR
- Franchissement de seuilsThreshold crossingFrench
- Franchissement de seuilsThreshold crossingFrench
- Document d'enregistrement universel 2024Universal registration documentFrenchZIP
- Franchissement de seuilsThreshold crossingFrench
- Franchissement de seuilsThreshold crossingFrench
- DBV Technologies to Participate in Upcoming AAAAI/WAO Joint CongressInside informationFR
About
- ISIN
- FR0010417345
- Ticker
- DBV
- LEI
- 969500PVBQFWQKVDMD80
- Sector
- Health care
- Founded
- 2002
- Country of registration
- FR
- Last filing
- 30/07/2026, 23:40
Description from Wikidata, CC0 licence.
Filing history
Filings per month
22
Sept 23May 24Jan 25Sept 25Aug 26
Document types
Across the whole archive